Paul Quinlan

2021

In 2021, Paul Quinlan earned a total compensation of $656.3K as General Counsel at Cymabay Therapeutics.

Compensation breakdown

Non-Equity Incentive Plan$152,872
Option Awards$103,380
Salary$394,000
Other$6,020
Total$656,272

Quinlan received $394K in salary, accounting for 60% of the total pay in 2021.

Quinlan also received $152.9K in non-equity incentive plan, $103.4K in option awards and $6K in other compensation.

Rankings

In 2021, Paul Quinlan's compensation ranked 10,090th out of 12,415 executives tracked by ExecPay. In other words, Quinlan earned more than 18.7% of executives.

ClassificationRankingPercentile
All
10,090
out of 12,415
19th
Division
Manufacturing
4,469
out of 5,505
19th
Major group
Chemicals And Allied Products
1,994
out of 2,375
16th
Industry group
Drugs
1,770
out of 2,096
16th
Industry
Pharmaceutical Preparations
1,319
out of 1,546
15th
Source: SEC filing on April 19, 2023.

Quinlan's colleagues

We found four more compensation records of executives who worked with Paul Quinlan at Cymabay Therapeutics in 2021.

2021

Sujal Shah

Cymabay Therapeutics

Chief Executive Officer

2021

Dennis Kim

Cymabay Therapeutics

Chief Medical Officer

2021

Lewis Stuart

Cymabay Therapeutics

Chief Commercial Officer

2021

Charles McWherter

Cymabay Therapeutics

President of R&D

News

You may also like